母源抗体对免疫口蹄疫油乳剂疫苗猪的血清学表现的干扰效应
研究评估O SKR 7/10口蹄疫疫苗在血清阴性猪中的效力及现场试验中的血清学表现。血清阴性猪接种后14天即对O Jincheon病毒完全保护,r1值≥0.92;但现场试验中即使双次接种组也未观察到满意的血清学升高,结论认为高母源抗体干扰了疫苗效果,疫苗可能需要改进。
要点
- O SKR 7/10疫苗在血清阴性猪中接种后14天即对O Jincheon病毒完全保护。
- O Jincheon与O SKR 2010病毒间r1值≥0.92,血清学关系强。
- 现场试验中即使双次接种组也未观察到满意的抗口蹄疫病毒血清学升高。
核心结论
- O SKR 7/10疫苗可能需要改进,以克服韩国全国强制接种母猪产生的高水平母源抗体的干扰效应。
研究设计与样本
- 研究评估O SKR 7/10疫苗在口蹄疫血清阴性猪中的效力,用O/Jincheon/SKR/2014(O Jincheon)病毒攻毒,并开展现场试验观察血清学表现。
主要发现
- 血清阴性猪接种后最早14天即对O Jincheon病毒完全保护。
- O Jincheon与O SKR 2010病毒之间r1值≥0.92。
- 现场试验中即使双次接种组也未观察到满意的抗口蹄疫病毒血清学升高。
关键数值与推荐
- O Jincheon与O SKR 2010病毒之间r1值≥0.92。
- 血清阴性猪接种后最早14天即对O Jincheon病毒完全保护。
临床怎么用
- 作者认为O SKR 7/10疫苗可能需要改进,以克服韩国全国强制接种母猪产生的高水平母源抗体的干扰效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To control foot-and-mouth disease (FMD) outbreaks that originated in Jincheon County in South Korea between 2014 and 2015, several commercial vaccines were studied for their efficacy and serological performance in the field. In this study, the efficacy of the O SKR 7/10 vaccine was evaluated by challenge with the FMD virus (FMDV) O/Jincheon/SKR/2014 (O Jincheon), which has the same O/SEA/Mya-98 lineage as the O/SKR/7/10 strain that was isolated in 2010 in South Korea, in FMD-seronegative pigs. Full protection against the O Jincheon virus was demonstrated as early as 14 days postvaccination, which was explained by the strong serological relationship (r1 value: ≥ 0.92) between the O Jincheon and O SKR 2010 viruses. However, in the field trial, no satisfactory serological elevations against FMDV were observed, even in the double-vaccinated groups. Therefore, it can be concluded that the O SKR 7/10 vaccine may need to be improved to overcome the interference effects from the high levels of maternally-derived antibodies generated due to the mandatory nationwide vaccination of sows in South Korea.
引用
- Kim J, Kim T, Hong JK, et al. The interference effect of maternally-derived antibodies on the serological performance of pigs immunized with a foot-and-mouth disease oil emulsion vaccine. Vaccine. 2019. PMID: 31892447. doi:10.1016/j.vaccine.2019.12.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。